Cramer’s #3 Speculative Stock for 2007

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Tonight Cramer continued his quest of delivering his favorite TOP 3 SPECULATIVE STOCKS FOR 2007.  Cramer started off with his #3 pick, or the second runner up for the speculative stocks.

Savient Pharma (SVNT) is his #1 pick.  He said it is up $4.00 and has been on a tear.  It is up against competition, and you can’t put more than 20% of your mad Money in any speculative stock and he thinks you need a basket of speculative stocks.  With 20% geared toward speculative stocks, you should still have 4 others.  Out of these you can expect one to scream and one to go bust.  Cramer says management is good because they sold off a drug for more than it was worth then cut the number of shares with a Dutch tender.  Their phase III gout drug looks promising and Cramer said there hasn’t been a gout treatment in about 40 years and there are 3 to 5 million Americans with gout.  Phase II results were amazing, and if they have 35% market penetration he thinks it will be $200 million to $400 million and the stock could double.

Below are his picks from Wednesday and Thursday for Growth and Value Picks for 2007:
#1 growth pick is the New York Stock Exchange (NYSE).
#2 is Apple (AAPL).
#3  is Cisco Systems (CSCO).

If you want to read through to the top VALUE PICKS for 2007 that Cramer gave on Wednesday night, here is the list:

1) Altria (MO)
2) Goldman Sachs (GS)
3) Halliburton (HAL)

Jon C. Ogg
January  5, 2007

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618